Get the Stockscreener App
0.4736
3.35%
-0.0164
After Hours:
.47
-0.0036
-0.76%
Aditxt Inc stock is traded at $0.4736, with a volume of 809.09K.
It is down -3.35% in the last 24 hours and down -70.40% over the past month.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.49
Open:
$0.48
24h Volume:
809.09K
Relative Volume:
0.38
Market Cap:
$4.13M
Revenue:
$749.50K
Net Income/Loss:
$-29.60M
P/E Ratio:
-0.00126
EPS:
-376.0263
Net Cash Flow:
$-22.09M
1W Performance:
-19.15%
1M Performance:
-70.40%
6M Performance:
-99.49%
1Y Performance:
-99.82%
1-Day Range:
$0.4529
$0.4879
1-Week Range:
$0.4529
$0.59
52-Week Range:
$0.4529
$380.00
Aditxt Inc Stock (ADTX) Company Profile
Name
Aditxt Inc
Sector
Industry
Phone
909-488-0844
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Aditxt Inc Stock (ADTX) Latest News
ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan
Aditxt receives positive FDA feedback on ATI-1801 development - Investing.com India
Evofem Biosciences enters agreements amid merger plans By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low of $0.53 amid market challenges - Investing.com
Aditxt receives positive FDA feedback on ATI-1801 development By Investing.com - Investing.com UK
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - StockTitan
Appili Therapeutics’ FDA Alignment and Aditxt Acquisition - TipRanks
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - The Manila Times
Aditxt Enters Major Investment Agreement with Evofem - TipRanks
Aditxt appoints Sylvia Hermina to board By Investing.com - Investing.com Canada
Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives - Quantisnow
Aditxt appoints Sylvia Hermina to board - Investing.com
Aditxt, Inc. Appoints Sylvia Hermina to its Board of Directors - Marketscreener.com
Evofem Biosciences, Inc. announced that it has received $2.28 million in funding from Aditxt, Inc. - Marketscreener.com
Is Aditxt Inc (NASDAQ: ADTX) Doomed From The Get-Go? - Stocks Register
Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - Quantisnow
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem - Quantisnow
ADTX stock touches 52-week low at $0.89 amid sharp decline - Investing.com UK
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time - StockTitan
Aditxt shares sold by major stakeholder HRT Financial for $29,874 - Investing.com South Africa
ADTX stock touches 52-week low at $1.07 amid steep annual decline - Investing.com
ADTX stock touches 52-week low at $1.07 amid steep annual decline By Investing.com - Investing.com South Africa
Why Aditxt Inc Stock Might Make Sense If Bought Today - Stocks Register
There is no way Aditxt Inc (ADTX) can keep these numbers up - SETE News
Aditxt Inc (ADTX) requires closer examination - US Post News
Market Insight: Aditxt Inc (ADTX)’s Notable Drop, Closing at 1.16 - The Dwinnex
Aditxt Inc: Analyzing ADTX Stock Trends - The InvestChronicle
Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy - Yahoo Finance
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test - MSN
Aditxt moves to acquire Appili Therapeutics - Investing.com India
Appili Therapeutics Corrects Shareholder Payout Terms - TipRanks
Aditxt moves to acquire Appili Therapeutics By Investing.com - Investing.com Canada
Appili Therapeutics – Press Release Correction - GlobeNewswire Inc.
Appili Therapeutics mails circular in connection with special meeting - TipRanks
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval - StockTitan
Appili Therapeutics Nears Acquisition by Aditxt Inc. - TipRanks
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders - The Manila Times
You might want to take a look at Aditxt Inc (ADTX) now - SETE News
Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time - Quantisnow
Aditxt faces Nasdaq delisting over share price rule By Investing.com - Investing.com South Africa
Aditxt faces Nasdaq delisting over share price rule - Investing.com India
Aditxt Inc: Navigating Market Fluctuations with a 0.18M Market Cap - The InvestChronicle
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem - Quantisnow
Aditx Therapeutics stock hits 52-week low at $1.58 - Investing.com India
Aditx Therapeutics stock hits 52-week low at $1.58 By Investing.com - Investing.com Australia
Aditxt Inc (ADTX)’s stock price range in the last year - US Post News
Aditxt Inc Stock (ADTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aditxt Inc Stock (ADTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):